Evidence map›Paper›PMID 22820868›Full record

ArticlePsychopharmacology2013

Attenuation of reinstatement of methamphetamine-, sucrose-, and food-seeking behavior in rats by fenobam, a metabotropic glutamate receptor 5 negative allosteric modulator.

Lucas R Watterson, Peter R Kufahl, Natali E Nemirovsky, Kaveish Sewalia, Lauren E Hood, M Foster Olive

Open access · greenAbstract read
In one paragraph

Article in Psychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Perirhinal Cortex mGlu5 Receptor Activation Reduces Relapse to Methamphetamine Seeking by Restoring Novelty Salience.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Article
  12. Article
  13. Article
  14. Article
  15. Astrocytic dysfunction and addiction: consequences of impaired glutamate homeostasis.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2014
    Review
  16. Role of cues and contexts on drug-seeking behaviour.British journal of pharmacology · 2014
    Review
  17. Article
  18. Review
  19. Article
  20. Stimulation of mGluR5 in the accumbens shell promotes cocaine seeking by activating PKC gamma.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lucas R WattersonDepartment of Psychology, Arizona State University, PO Box 871104, 950 S McAllister Avenue, Tempe, AZ 85287, USA.
Peter R Kufahl
Natali E Nemirovsky
Kaveish Sewalia
Lauren E Hood
M Foster Olive
Arizona State University · US

Funding

mGluR5 antagonists for methamphetamine addictionR01DA025606 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OLIVE, M. FOSTER · 2009 to 2012
$1.2M
NIDA NIH HHS DA025606NIDA NIH HHS R01 DA025606
6 · The paper itself

Abstract

rationaleMethamphetamine (METH) is a highly potent and addictive psychostimulant with severe detrimental effects to the health of users. Currently, METH addiction is treated with a combination of cognitive and behavioral therapies, but these traditional approaches suffer from high relapse rates. Furthermore, there are currently no pharmacological treatment interventions approved by the FDA specifically for the treatment of METH addiction.

objectivesMetabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators (NAMs) have shown promise in significantly attenuating drug self-administration and drug-seeking in reinstatement paradigms. However, studies assessing the potential efficacy of mGluR5 NAMs that have been tested in human subjects are lacking. The current study sought to assess the effect of the mGluR5 NAM fenobam on METH-seeking behavior.

methodsRats were trained to self-administer METH (0.05 mg/kg i.v.), and following extinction, tested for effects of fenobam (5, 10, or 15 mg/kg intraperitoneal) on cue- and drug-induced reinstatement of METH-seeking. To determine if fenobam also alters reinstatement of seeking of natural reinforcers, separate groups of rats were trained to self-administer sucrose or food pellets and were tested for the effects of fenobam on cue-induced reinstatement of sucrose- and food-seeking.

resultsFenobam attenuated drug- and cue-induced reinstatement of METH-seeking behavior at doses of 10 and 15 mg/kg. Fenobam also attenuated cue-induced reinstatement of sucrose- and food-seeking at all doses tested.

conclusionsThe mGluR5 NAM fenobam attenuates the reinstatement of METH-seeking behavior, but these effects may be due to nonspecific suppression of general appetitive behaviors.

Indexed as

Allosteric RegulationAnimalsCuesDose-Response Relationship, DrugFeeding BehaviorImidazolesMaleMethamphetamineRatsRats, Sprague-DawleyReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateReinforcement ScheduleSelf AdministrationSucrosefenobamGRM5 protein, humanGrm5 protein, ratImidazolesMethamphetamineReceptor, Metabotropic Glutamate 5Receptors, Metabotropic GlutamateSucrose

Identifiers

PMID22820868
PMCPMC3742304
OpenAlexW2035850746

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.